Group I | | |
Normal | 11 | 9 |
Non-proliferative fibrocystic change | 12 | 10 |
Ductal or lobular hyperplasia | 9 | 8 |
Group II | | |
Atypical ductal or lobular hyperplasia | 11 | 9 |
Ductal/lobular carcinoma in situ | 13 | 11 |
Group III | | |
Ductal carcinoma, grade I | 17 | 14 |
Ductal carcinoma, grade II | 19 | 16 |
Ductal carcinoma, grade III | 15 | 12 |
Lobular carcinoma, grade I–III | 13 | 11 |
Total specimens | 120 | 100 |
Hormone receptor status (group III) |
ER+ | 34 | 53 |
ER− | 30 | 47 |
PR+ | 33 | 52 |
PR− | 31 | 48 |
Mean age (years) | |
Group I | 54 (range, 22–68) |
Group II | 52 (range, 29–62) |
Group III | 59 (range, 32–90) |
Menopausal/postmenopausal | |
Group I | 25 | 78% |
Group II | 20 | 83% |
Group III | 60 | 92% |